Perkins Capital Management Inc. Has $1.68 Million Holdings in MDxHealth SA (NASDAQ:MDXH)

Key Points

• Perkins Capital Management Inc. increased its stake in MDxHealth SA by 20.1% in the first quarter, now owning over 1.18 million shares, which represents 1.8% of its portfolio.
• MDxHealth's shares currently trade at $2.49, with a market cap of $117.75 million, and the company reported negative earnings per share of ($0.19) in its latest quarterly results.
• Several analysts have updated their ratings on MDxHealth, with Wall Street Zen upgrading to a "hold" and Craig Hallum initiating coverage with a "buy" rating and a price target of $8.00.

Perkins Capital Management Inc. grew its holdings in MDxHealth SA (NASDAQ:MDXH - Free Report) by 20.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,181,475 shares of the company's stock after purchasing an additional 198,000 shares during the quarter. MDxHealth makes up approximately 1.8% of Perkins Capital Management Inc.'s holdings, making the stock its 16th biggest holding. Perkins Capital Management Inc. owned about 2.50% of MDxHealth worth $1,678,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of MDXH. Samjo Management LLC boosted its stake in shares of MDxHealth by 130.9% in the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock valued at $4,324,000 after purchasing an additional 1,034,312 shares during the last quarter. AWM Investment Company Inc. boosted its stake in MDxHealth by 11.1% during the 4th quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock worth $11,189,000 after acquiring an additional 471,290 shares during the last quarter. Northern Trust Corp bought a new position in MDxHealth during the 4th quarter worth approximately $1,033,000. Renaissance Technologies LLC boosted its stake in MDxHealth by 715.2% during the 4th quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock worth $292,000 after acquiring an additional 108,000 shares during the last quarter. Finally, Northern Right Capital Management L.P. bought a new position in MDxHealth during the 4th quarter worth approximately $246,000.

MDxHealth Stock Down 0.6%

MDXH stock traded down $0.01 during mid-day trading on Thursday, hitting $2.42. 24,004 shares of the company were exchanged, compared to its average volume of 80,201. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.92 and a current ratio of 2.00. The firm has a market cap of $114.25 million, a P/E ratio of -2.10 and a beta of 1.31. The firm's 50 day simple moving average is $2.19 and its 200 day simple moving average is $1.89. MDxHealth SA has a 1-year low of $1.35 and a 1-year high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $24.29 million for the quarter, compared to analyst estimates of $22.62 million. MDxHealth had a negative return on equity of 492.11% and a negative net margin of 41.02%. On average, sell-side analysts predict that MDxHealth SA will post -1.15 EPS for the current fiscal year.

Analyst Ratings Changes

MDXH has been the topic of several recent analyst reports. Wall Street Zen raised shares of MDxHealth to a "hold" rating in a research note on Saturday, May 24th. Craig Hallum initiated coverage on shares of MDxHealth in a research note on Thursday, July 17th. They set a "buy" rating and a $8.00 price objective on the stock.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.